BRIEF published on 07/17/2025 at 09:05, 4 months 18 days ago MAX Automation SE Faces Market Challenges but Maintains BUY Rating Market Challenges Order Intake BUY Rating Financial Forecast MAX Automation
PRESS RELEASE published on 07/17/2025 at 09:00, 4 months 18 days ago Original-Research: MAX Automation SE (von NuWays AG): BUY Research update on MAX Automation SE by NuWays AG. Company revises FY25 guidance due to challenging market conditions and reduced order intake. Portfolio restructuring to drive future cost efficiency and margin improvement Market Conditions NuWays AG Research Update MAX Automation SE Portfolio Restructuring
BRIEF published on 07/15/2025 at 19:05, 4 months 20 days ago MAX Automation SE Lowers 2025 Financial Forecast EBITDA Economic Uncertainty Financial Forecast MAX Automation SE 2025 Sales
PRESS RELEASE published on 07/15/2025 at 19:00, 4 months 20 days ago EQS-Adhoc: MAX Automation SE revises forecast for financial year 2025 MAX Automation SE revises forecast downward for financial year 2025 due to weaker order intake and one-off expenses. Sales projected between EUR 300-340 million, EBITDA between EUR 12-18 million EBITDA MAX Automation SE Forecast Revision Sales Projection Financial Year 2025
BRIEF published on 05/23/2025 at 15:05, 6 months 12 days ago MAX Automation SE Concludes Ordinary General Meeting 2025 Investment Company Frankfurt Stock Exchange Shareholder Approval MAX Automation SE General Meeting 2025
PRESS RELEASE published on 05/23/2025 at 15:00, 6 months 12 days ago MAX Automation SE: Ordinary General Meeting 2025 held MAX Automation SE held its Ordinary General Meeting 2025 in Hamburg. Resolutions proposed by the management were approved. For more information, visit www.maxautomation.com/hv2025 Management Resolutions Ordinary General Meeting MAX Automation SE Hamburg
BRIEF published on 05/16/2025 at 09:05, 6 months 19 days ago MAX Automation SE Sees Challenges but Maintains Optimistic Outlook Q1 Results Project Delays EBITDA Performance Sales Guidance MAX Automation
PRESS RELEASE published on 05/16/2025 at 09:00, 6 months 19 days ago Original-Research: MAX Automation SE (von NuWays AG): BUY MAX Automation SE released Q1 results showing soft numbers due to project postponements. Despite this, FY25 guidance was confirmed. Analyst recommends BUY with target price EUR 7.00 Analyst Recommendation Q1 Results MAX Automation SE FY25 Guidance Project Postponements
BRIEF published on 05/15/2025 at 07:35, 6 months 20 days ago MAX Automation SE Faces Challenging First Quarter in 2025 Order Intake Sales Decline Economic Conditions First Quarter 2025 Forecast 2025
PRESS RELEASE published on 05/15/2025 at 07:30, 6 months 20 days ago MAX Automation SE reports challenging first quarter – Forecast for 2025 confirmed MAX Automation SE reports challenging first quarter with declining sales and order intake but confirms forecast for 2025 amid economic uncertainties Sales Order Intake Forecast First Quarter MAX Automation SE
Published on 12/05/2025 at 02:35, 4 hours 54 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 29 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 24 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 29 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 28 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 58 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 38 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 3 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 14 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:00, 13 hours 29 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 44 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 13 hours 45 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 13 hours ago Declaration of voting rights at the end of November 2025
